Sugi Predict

Sugi Predict / Compounds / SCHEMBL4092716

SCHEMBL4092716

SCHEMBL4092716

Cc1ccccc1NS(=O)(=O)c1cccc(NC(=O)NC(c2ccc(C(=O)NCCC(=O)O)cc2)c2ccc(C3CCCCC3)cc2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CASP3 P42574 1/20 0.44
▸ SENP8 Q96LD8 1/20 0.44
▸ SENP7 Q9BQF6 1/20 0.44
▸ SENP6 Q9GZR1 1/20 0.44
▸ GCGR P47871 1/20 0.43
▸ MAPT P10636 5/20 0.42
▸ LMNA P02545 4/20 0.42
▸ ALDH1A1 P00352 3/20 0.42
▸ KDM4E B2RXH2 2/20 0.42
▸ HTT P42858 2/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ MAPK1 P28482 2/20 0.42
▸ TP53 P04637 1/20 0.42
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ POLB P06746 1/20 0.40
▸ OPRM1 P35372 1/20 0.40
▸ OPRK1 P41145 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ FNTA P49354 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4091464 0.92 GCGR (0.43) GCGRMAPTLMNAALDH1A1KDM4E
SCHEMBL4087821 0.87 GCGR (0.48) GCGRMAPTALDH1A1MEN1KMT2A
SCHEMBL6751734 0.86 ALDH1A1 (0.43) GCGRMAPTLMNAALDH1A1KDM4E
SCHEMBL4092719 0.84 SMN1; SMN2 (0.48) GCGRMAPTLMNAALDH1A1HTT
SCHEMBL2651718 0.84 GCGR (0.50) GCGRMAPTLMNAHTTCYP2D6
SCHEMBL6751732 0.83 MAPT (0.45) GCGRMAPTLMNAALDH1A1KDM4E
SCHEMBL4091466 0.83 GCGR (0.46) GCGRMAPTLMNAALDH1A1KDM4E
SCHEMBL4085768 0.83 GCGR (0.42) CASP3SENP8SENP7SENP6GCGR
SCHEMBL2653146 0.83 GCGR (0.50) GCGRMAPTALDH1A1MEN1KMT2A
SCHEMBL6753873 0.82 ALDH1A1 (0.43) GCGRMAPTLMNAALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 — — US disclosed
EP-1183229-B1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK AS (DK) 2005-10-26 — — EP disclosed
US-20050203108-A1 Glucagon antagonists/inverse agonists PFIZER INC 2005-09-15 — — US disclosed
US-6875760-B2 Glucagon antagonists/inverse agonists NOVO NORDISK A/S (DK) 2005-04-05 — — US disclosed
US-20030220350-A1 Glucagon antagonists/inverse agonists PFIZER INC 2003-11-27 — — US disclosed
US-6503949-B1 Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity NORO NORDISK A/S (DK) 2003-01-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203108-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR CASP3 2703/4885SENP8 3574/4885SENP7 3299/4885
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists GLP1R, GPR119, GCGR CASP3 2703/4885SENP8 3574/4885SENP7 3299/4885
US-20030220350-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR CASP3 2703/4885SENP8 3574/4885SENP7 3299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.